



COPIES OF PAPERS
ORIGINALLY FILED

1644
#6
ATTORNEY DOCKET NO. 14014.0353U2
SERIAL NO. 09/856,544

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

LUDVIKSSON *et al.*

Confirmation No. 9811

Serial No. 09/856,544

Filed: November 23, 1999

For: "ANTAGONISTS OF THE ALPHA E BETA 7
INTEGRIN AS THERAPEUTIC AGENTS
FOR INFLAMMATORY DISEASES"

RECEIVED
JUN 14 2002
TECH CENTER 1600/2900

Group Art: 1644

Examiner: Haddad, M.

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

June 6, 2002

Sir:

This is in response to the Office Action dated May 6, 2002, wherein restriction of the claims of the above-identified application is required. The Office Action requires restriction to one of the following seven groups of claims:

Group I: Claims 1-23 and 26-28, drawn to a method of treating or preventing inflammation in a subject, comprising administering to the subject an antagonist to $\alpha E\beta 7$ or further comprising administering another therapeutic agent wherein the other therapeutic agent is an $\alpha 4\beta 7$ Mab.

Group II; Claims 1-21, 24 and 29, drawn to a method of treating or preventing inflammation in a subject, comprising administering to the subject an antagonist to $\alpha E\beta 7$ or further comprising administering another therapeutic agent wherein the other therapeutic agent is a cytokine.